Medlab Clinical Limited (ASX: MDC), the Australian company commercialising an enhanced drug delivery platform to maximise the efficacy of medicines has outlined its growth strategy for US and global investors at the prestigious annual Jefferies Healthcare Conference.
Medlab Clinical’s Founder, CEO and Managing Director Dr Sean Hall told the conference, “The progress of our novel synthetic cannabinoid formulation for non-opioid pain has put Medlab at the forefront of the efforts to develop clinically validated non-opioid alternatives for cancer bone pain.”
Dr Sean Hall said, “Medlab’s move to a synthetic compound for its pending Phase III trial brings greater certainty to the delivery of a pharmaceutical-grade product at industrial scale for global markets.”
Dr Sean Hall said, “Medlab was focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible.” He shared with the audience that Medlab had identified multiple revenue-generating partnering opportunities for its NanoCelle® drug delivery platform which can improve the efficacy of multiple medicines and therapeutics.
Dr Sean Hall, on behalf of Medlab, would like to thank Jefferies Financial Group Inc for the opportunity to present our vision to such an influential global audience.